Patients treated with PPIs who develop skin lesions (especially in sun-exposed areas) accompanied by arthralgia should avoid exposing the skin to sunlight. Prescribers should consider:
- SCLE as a possible diagnosis
- stopping use of the PPI unless it is imperative for a serious acid-related condition
- that a patient who develops SCLE with a particular PPI may be at risk of the same reaction with another PPI.
SCLE is a non-scarring dermatosis that can develop in sun-exposed areas. It is characterised by polycyclic erythematous scaly papular plaques or confluent psoriasiform papulosquamous lesions, which may be accompanied by arthralgia. Drug-induced SCLE can occur weeks, months or even years after exposure to the drug.